title: Impaired metabolic effects of a thyroid hormone receptor beta-selective agonist in a mouse model of diet-induced obesity.
abstract: BACKGROUND
  The use of selective agonists of the thyroid hormone receptor isoform beta (TRbeta) has been linked to metabolic improvement in animal models of diet-induced obesity, nonalcoholic liver disease, and genetic hypercholesterolemia.
  
  
  METHODS
  To identify potential target tissues of such compounds, we exposed primary murine brown adipocytes and skeletal myocytes for 24 hours to 50 nM GC-24, a highly selective TRbeta agonist. GC-24 (17 ng/[g BW.day] for 36 days) was also tested in a mouse model of diet-induced obesity.
  
  
  RESULTS
  While the brown adipocytes responded to GC-24, with 17%-400% increases in the expression of 12 metabolically relevant genes, the myocytes remained largely unresponsive to GC-24 treatment. In control mice kept on chow diet, GC-24 treatment accelerated energy expenditure by about 15% and limited body weight gain by about 50%. However, in the obese animals the GC-24-mediated reduction in body weight gain dropped to only 20%, while energy expenditure remained unaffected. In addition, an analysis of gene expression in the skeletal muscle, brown adipose tissue, and liver of these obese animals failed to identify a conclusive GC-24 transcriptome footprint.
  
  
  CONCLUSIONS
  Feeding a high-fat diet impairs most of the beneficial metabolic effects associated with treatment with TRbeta-selective agonists.
authors.affiliation: Division of Endocrinology, Diabetes, and Metabolism, Miller School of Medicine, University of Miami, Florida 33136, USA.
authors.forename: Melany
authors.initials: M
authors.lastname: Castillo
authors.forename: Beatriz C G
authors.initials: BC
authors.lastname: Freitas
authors.forename: Matthew L
authors.initials: ML
authors.lastname: Rosene
authors.forename: Rafael A
authors.initials: RA
authors.lastname: Drigo
authors.forename: Renata
authors.initials: R
authors.lastname: Grozovsky
authors.forename: Rui M B
authors.initials: RM
authors.lastname: Maciel
authors.forename: Mary Elizabeth
authors.initials: ME
authors.lastname: Patti
authors.forename: Miriam O
authors.initials: MO
authors.lastname: Ribeiro
authors.forename: Antonio C
authors.initials: AC
authors.lastname: Bianco
mesh_terms: D000085:Acetates / Q000009:adverse effects* / Q000627:therapeutic use*; D052437:Adipocytes, Brown / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001559:Benzhydryl Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002153:Calorimetry, Indirect; D002478:Cells, Cultured; D004032:Diet; D004734:Energy Metabolism / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects; D008297:Male; D008660:Metabolism / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D018485:Muscle Fibers, Skeletal / Q000187:drug effects / Q000378:metabolism; D009765:Obesity / Q000188:drug therapy*; D009929:Organ Size / Q000187:drug effects; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D037042:Thyroid Hormone Receptors beta / Q000819:agonists*; D014284:Triiodothyronine / Q000494:pharmacology
chemical_list: D000085:Acetates; D019440:Anti-Obesity Agents; D001559:Benzhydryl Compounds; C483767:GC 24 compound; D012333:RNA, Messenger; D037042:Thyroid Hormone Receptors beta; D014284:Triiodothyronine
references.citation: J Steroid Biochem Mol Biol. 2008 Sep;111(3-5):262-7
references.pmid: 18621127
references.citation: Thyroid. 2007 May;17(5):433-45
references.pmid: 17542673
references.citation: Endocrinology. 2006 Apr;147(4):1735-43
references.pmid: 16396983
references.citation: J Endocrinol. 2007 Apr;193(1):21-9
references.pmid: 17400799
references.citation: Endocrinology. 2004 Nov;145(11):5252-8
references.pmid: 15297436
references.citation: Rev Endocr Metab Disord. 2000 Jan;1(1-2):27-33
references.pmid: 11704989
references.citation: N Engl J Med. 1994 Sep 29;331(13):847-53
references.pmid: 8078532
references.citation: Endocrinology. 2004 Apr;145(4):1656-61
references.pmid: 14701670
references.citation: Diabetes. 2004 Mar;53(3):577-84
references.pmid: 14988240
references.citation: Mol Endocrinol. 2001 Mar;15(3):467-75
references.pmid: 11222747
references.citation: J Cell Biol. 1994 Jun;125(6):1275-87
references.pmid: 8207057
references.citation: Endocrinology. 2003 Dec;144(12):5480-7
references.pmid: 12959999
references.citation: Am J Physiol. 1999 Jan;276(1):E179-87
references.pmid: 9886965
references.citation: Biosci Rep. 2005 Jun-Aug;25(3-4):191-208
references.pmid: 16283553
references.citation: Thyroid. 2008 Feb;18(2):197-203
references.pmid: 18279020
references.citation: Cell Tissue Res. 2005 Aug;321(2):233-41
references.pmid: 15947969
references.citation: J Endocrinol. 2009 Nov;203(2):291-9
references.pmid: 19713219
references.citation: Endocrinology. 2000 Sep;141(9):3057-64
references.pmid: 10965874
references.citation: Am J Physiol Endocrinol Metab. 2003 Nov;285(5):E1135-41
references.pmid: 12965872
references.citation: Chem Biol. 1998 Jun;5(6):299-306
references.pmid: 9653548
references.citation: J Clin Invest. 2001 Nov;108(9):1379-85
references.pmid: 11696583
references.citation: Curr Vasc Pharmacol. 2007 Apr;5(2):141-54
references.pmid: 17430219
references.citation: J Clin Invest. 2001 Jul;108(1):97-105
references.pmid: 11435461
references.citation: Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15490-5
references.pmid: 17878314
references.citation: Endocr Rev. 2008 Dec;29(7):898-938
references.pmid: 18815314
references.citation: N Engl J Med. 2009 Apr 9;360(15):1553-6
references.pmid: 19357412
references.citation: FASEB J. 2008 Aug;22(8):2981-9
references.pmid: 18434432
references.citation: Mol Cell Biol. 2001 Jan;21(1):319-29
references.pmid: 11113206
references.citation: Physiol Rev. 2001 Jul;81(3):1097-142
references.pmid: 11427693
references.citation: J Clin Endocrinol Metab. 2009 Sep;94(9):3521-9
references.pmid: 19549744